中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2015年
24期
28-29
,共2页
BiPAP无创通气%慢性阻塞性肺疾病%Ⅱ型呼吸衰竭
BiPAP無創通氣%慢性阻塞性肺疾病%Ⅱ型呼吸衰竭
BiPAP무창통기%만성조새성폐질병%Ⅱ형호흡쇠갈
BiPAP non-invasive ventilation%Chronic obstructive pulmonary disease%TypeⅡrespiratory failure
目的:探讨BiPAP无创通气治疗慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭的临床疗效。方法将40例慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的住院患者随机分成两组,对照组(n=20)予以常规治疗,治疗组(n=20)在常规治疗基础上加用BiPAP无创通气治疗,比较两组呼吸、心率、PaO2、PaCO2、插管率、病死率及住院时间。结果治疗后两组患者呼吸、心率、PaO2、PaCO2均较治疗前明显改善(P<0.05)。与对照组比较,治疗组呼吸、心率、PaO2、PaCO2改善更明显(P<0.05)。治疗组插管率及病死率明显低于对照组(P<0.05),住院时间明显短于对照组(P<0.05)。结论BiPAP无创通气对COPD合并Ⅱ型呼吸衰竭进行治疗能够明显改善患者呼吸、心率、PaO2及PaCO2,能够明显降低插管率及病死率,缩短住院时间。
目的:探討BiPAP無創通氣治療慢性阻塞性肺疾病(COPD)閤併Ⅱ型呼吸衰竭的臨床療效。方法將40例慢性阻塞性肺疾病閤併Ⅱ型呼吸衰竭的住院患者隨機分成兩組,對照組(n=20)予以常規治療,治療組(n=20)在常規治療基礎上加用BiPAP無創通氣治療,比較兩組呼吸、心率、PaO2、PaCO2、插管率、病死率及住院時間。結果治療後兩組患者呼吸、心率、PaO2、PaCO2均較治療前明顯改善(P<0.05)。與對照組比較,治療組呼吸、心率、PaO2、PaCO2改善更明顯(P<0.05)。治療組插管率及病死率明顯低于對照組(P<0.05),住院時間明顯短于對照組(P<0.05)。結論BiPAP無創通氣對COPD閤併Ⅱ型呼吸衰竭進行治療能夠明顯改善患者呼吸、心率、PaO2及PaCO2,能夠明顯降低插管率及病死率,縮短住院時間。
목적:탐토BiPAP무창통기치료만성조새성폐질병(COPD)합병Ⅱ형호흡쇠갈적림상료효。방법장40례만성조새성폐질병합병Ⅱ형호흡쇠갈적주원환자수궤분성량조,대조조(n=20)여이상규치료,치료조(n=20)재상규치료기출상가용BiPAP무창통기치료,비교량조호흡、심솔、PaO2、PaCO2、삽관솔、병사솔급주원시간。결과치료후량조환자호흡、심솔、PaO2、PaCO2균교치료전명현개선(P<0.05)。여대조조비교,치료조호흡、심솔、PaO2、PaCO2개선경명현(P<0.05)。치료조삽관솔급병사솔명현저우대조조(P<0.05),주원시간명현단우대조조(P<0.05)。결론BiPAP무창통기대COPD합병Ⅱ형호흡쇠갈진행치료능구명현개선환자호흡、심솔、PaO2급PaCO2,능구명현강저삽관솔급병사솔,축단주원시간。
Objective?To investigate the effect of bilevel positive airway pressure ventilation on chronic obstructive pulmonary disease combined with typeⅡrespiratory failure. Methods?Forty patients with chronic obstructive pulmonary disease combined with typeⅡrespiratory failure were divided into control group and treatment group. Patients in control group (n=20) were given conventional general treatment only while patients in treatment group (n=20) were given BiPAP ventilation besides conventional treatment. The changes of respiration, heart rate, PaO2, PaCO2, cannula rate, mortality and hospitalized between the two groups were compared. Results?The respiration, heart rate, PaO2 and PaCO2 improved signiifcantly after treatment as compared with baseline in both groups (P<0.05). The cannula rate and mortality in treatment group was signiifcantly lower than that in control group (P<0.05). The hospitalized time of treatment group was shorter than control group (P<0.05). Conclusion?BiPAP ventilation in treatment with chronic obstructive pulmonary disease combined with typeⅡrespiratory failure can improve respiration, heart rate, PaO2 and PaCO2, degrade cannula rate and mortality, shorten hospitalized time.